bioTheranostics discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer.

The bioT3 Metastatic Cancer Solution provides actionable genomic information for accurate diagnosis and treatment of metastatic cancer patients.

CancerTYPE ID® Most validated gene expression-based assay to help achieve an accurate diagnosis.
CancerTREATMENT NGS+ Combines Next Generation Sequencing (NGS) with selected IHC/FISH tests to identify biomarkers linked to targeted treatments.
Breast Cancer IndexSM provides full risk assessment, with the unique ability to predict both early and late recurrence, as well as likelihood of benefit from extended endocrine therapy.